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Abstract
Background: The ability of bacteria to rapidly evolve resistance to antibiotics is a critical public health problem. Resistance
leads to increased disease severity and death rates, as well as imposes pressure towards the discovery and development of
new antibiotic therapies. Improving understanding of the evolution and genetic basis of resistance is a fundamental goal in
the field of microbiology.
Results: We have applied a new genomic method, Scalar Analysis of Library Enrichments (SCALEs), to identify genomic
regions that, given increased copy number, may lead to aminoglycoside resistance in Pseudomonas aeruginosa at the
genome scale. We report the result of selections on highly representative genomic libraries for three different
aminoglycoside antibiotics (amikacin, gentamicin, and tobramycin). At the genome-scale, we show significant (p,0.05)
overlap in genes identified for each aminoglycoside evaluated. Among the genomic segments identified, we confirmed
increased resistance associated with an increased copy number of several genomic regions, including the ORF of PA5471,
recently implicated in MexXY efflux pump related aminoglycoside resistance, PA4943-PA4946 (encoding a probable GTP-
binding protein, a predicted host factor I protein, a d 2-isopentenylpyrophosphate transferase, and DNA mismatch repair
protein mutL), PA0960–PA0963 (encoding hypothetical proteins, a probable cold shock protein, a probable DNA-binding
stress protein, and aspartyl-tRNA synthetase), a segment of PA4967 (encoding a topoisomerase IV subunit B), as well as a
chimeric clone containing two inserts including the ORFs PA0547 and PA2326 (encoding a probable transcriptional
regulator and a probable hypothetical protein, respectively).
Conclusions: The studies reported here demonstrate the application of new a genomic method, SCALEs, which can be used
to improve understanding of the evolution of antibiotic resistance in P. aeruginosa. In our demonstration studies, we
identified a significant number of genomic regions that increased resistance to multiple aminoglycosides. We identified
genetic regions that include open reading frames that encode for products from many functional categories, including
genes related to O-antigen synthesis, DNA repair, and transcriptional and translational processes.
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Introduction
The objective of this work is to adapt the SCalar Analysis of
Library Enrichments (SCALEs) method [1] for use in Pseudomonas
aeruginosa. The aspiration is that this genomic tool would allow the
genome-wide identification of a large number of intrinsic genomic
regions and genes related to antibiotic resistance or the evolution
of resistance. Specifically, we examined the system of genetic
regions related to resistance of P. aeruginosa to the aminoglycoside
class of antibiotics. This is also the first work in which SCALEs,
with modification, has been applied to an organism other than E.
coli.
Antibiotic resistance is a growing clinical problem [2,3] resulting
in increased disease severity, mortality rates, and healthcare costs.
Clinically resistant strains often contain multiple resistance
mechanisms, which may contribute to resistance in either an
additive or multiplicative fashion [4–6]. The genes underlying
such mechanisms can evolve via mutation of ancestral genes,
including housekeeping genes and metabolic genes [7,8]. Thus,
the process of evolving new resistance phenotypes (aside from the
acquisition of new genetic material) depends upon the reservoir of
potential resistance genes maintained within a particular bacteri-
um [9–11]. Identifying these potential resistance genes can be
difficult or laborious using conventional methods such as
homology comparison to known resistance genes or genetic tool
such as traditional library screening [12] or transposon mutagen-
esis [13]. As a result, efforts to better predict the evolution of
resistance remain challenging [5,8,14–16].
P. aeruginosa is an opportunistic pathogen that is noted for its
ability to adapt to a variety of niches and substances that are
considered harmful to microorganisms, including antibiotics
[17–20]. Antibiotics provide pressure for bacteria to acquire or
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organisms is a model of active evolution. Strains able to develop
resistance will proliferate while those unable to develop resistance
are unable to survive or flourish. Patients that are administered
multiple antibiotics or undergo extended antibiotic therapy, such
as cystic fibrosis patients, are at higher risk of developing infections
with resistant bacteria. P. aeruginosa is frequently responsible for
severe infections in those affected by cystic fibrosis. Additionally, in
hospitals where antibiotics are used extensively, thus providing an
environment conducive to evolving resistance, P. aeruginosa is
frequently isolated (www.cdc.gov).
The aminoglycosides are a class of bactericidal (with a few
exceptions) natural or semi-synthetic antibiotics that act by
binding to the 30S ribosome with noted effects of inhibition of
DNA and protein synthesis, disruption of peptide chain elonga-
tion, interference with peptide chain release from ribosomes, and
loss of cell membrane integrity [21–24]. Resistance to aminogly-
cosides is well established, often involving aminoglycoside
modifying enzymes, ribosomal mutations, altered cell permeabil-
ity, efflux pumps [25], or ribosomal methylation by 16S rRNA
methylase [26]. Nevertheless, the precise mechanisms by which
aminoglycosides cause cell death have yet to be fully elucidated.
The SCALEs method involves several steps. The first step
involves fragmenting genomic DNA, selecting specific sized
genomic fragments, and ligating these fragments into a suitable
backbone vector to construct several highly representative (.99%
probability that the entire genome is present) plasmid-based
genomic libraries of distinct insert size. These genomic libraries
are individually transformed into an appropriate host strain,
pooled, and subjected to a selective condition to enrich the
population for clones best fitted to survive during the selective
condition. The plasmid DNA is then extracted from the selected
pool of clones and hybridized to a DNA microarray containing
probes designed from the genome of the organism from which the
genomic libraries were constructed. The multiple size libraries act
in a cumulative effect to create signal intensity patterns on the
microarray. SCALEs then uses a decomposition of the data which
correlates signal intensity of probes on the DNA microarray to
genomic position and allows the deciphering of genomic segments
enriched within the selected populations [1]. This method goes
beyond traditional methods that rely upon conventional sequenc-
ing that are limited to the identification of only a handful of the
most-fit clones. SCALEs enables the direct assessment of increased
dosage effects on cellular phenotypes, which, while not encom-
passing all possible mutations, has been shown to represent a
major source of evolutionary novelty in nature and to mimic many
effects (i.e. gene overexpression, altered regulation, etc.) that might
also result from point mutations [27].
For this study, we created three highly representational different
sized genomic libraries of P. aeruginosa PAO1 within the vector
pBTB-1 [28] . Vector pBTB-1 is a low copy number broad host
range plasmid containing a b-lactamase resistance marker, a
pBAD promoter upstream of the cloning site, as well as
transcriptional terminators flanking the cloning site to aid in
insert stability. These libraries were transformed into the
recombination-deficient P. aeruginosa PAO1 mutant, PAO2003,
pooled, and parallel selections performed to identify via traditional
sequencing or SCALEs the genomic regions capable of conferring
increased tolerance to amikacin, gentamicin, or tobramycin.
These antibiotics are all structurally related but have differing
substitution patterns on their aminoglycoside backbones. These
differences in structure and substitution patterns impact the
activity of each antibiotic [29]. We chose to study three different
aminoglycosides in attempts to identify genomic regions capable of
conferring resistance to not only a specific aminoglycoside, but also
to the more general class of aminoglycosides. Our analysis efforts
focused first on validating the reliability of the data provided by
the adapted SCALEs methodology and on assessing the enriched
resistance regions as well as the overlap among enrichment
patterns obtained for each aminoglycoside.
Results
The overall objective of this work was to adapt the SCALEs
methodology to identify at the genome-scale a reservoir of
potential aminoglycoside resistance genes present in P. aeruginosa.
We first created and characterized libraries of mixed insert size
(see Methods) and then performed growth selections on mixtures
of such libraries. Next, we used conventional sequencing and
Affymetrix P. aeruginosa Genome arrays to identify genomic regions
present in library populations before and after selection. Finally,
we assessed overlap among resistance regions enriched in each
aminoglycoside selection.
Growth selections to identify resistant clones
Selections were performed by mixing equal molar concentra-
tions of 1 kb, 2 kb, and 4 kb insert sized genomic libraries within
the host strain P. aeruginosa PAO2003, allowing those mixtures to
recover in non-selective conditions for 1 hour, and then spreading
an equal numbers of cells onto plates containing increasing
concentrations of gentamicin, tobramycin, or amikacin. All
selections resulted in colonies growing on concentrations of
antibiotic 1–2 fold greater than the concentration at which the
PAO2003 or the PAO2003 strain containing the empty vector
backbone were able to grow, indicating that genomic insert
contained within surviving library clones were providing a
moderate selective advantage. The selections were performed in
duplicate, with comparable number of surviving clones achieved
each time. The gentamicin library selections had colonies that
grew upon concentrations up to 16 mg/ml compared to 4 mg/ml
for the controls. Tobramycin library selections had colonies
growing up to 4 mg/ml, with a lawn of colonies growing at 2 mg/
ml, which was the concentration sufficient to prevent growth of the
control samples. Amikacin library selections had clones growing
on concentrations of up to 16 mg/ml while the control population
was capable of growing on concentrations up to 4 mg/ml. Control
selections did have a small number of colonies that grew on
antibiotic concentrations higher than the concentration that was
necessary to kill the majority of the cells. This raises the possibility
that control populations had a small number of mutants or
persister clones, which emphasized the necessity of confirming that
the resistance of selected library clones was due to increased copy
of plasmid-based genomic insert DNA.
Confirmation and Analysis of Resistance Clones
Ten clones were taken randomly from each selective plate to
identify genomic regions contained within plasmid DNA and
confirm resistance phenotypes. This also allowed us to assess the
diversity among the surviving selected clones and assess the
necessity of microarray studies. Here, a clone is defined as a
PAO2003 transformant containing a distinct region of genomic
DNA within its plasmid based insert DNA. The genomic inserts
were identified via sequencing of plasmid DNA isolated from
selected clones. Of the 40 clones chosen for further analysis, 31
contained inserts containing overlapping genomic regions. Eight
clones were chosen that contained different genomic inserts, their
plasmids extracted, and these plasmids transformed back into P.
aeruginosa PAO2003. Once transformed, these clones were
P. aeruginosa Resistance Genes
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resistance to other aminoglycosides. Five of the eight distinct
clones were found to have increased resistance to the tested
aminoglycosides (Table 1). Interestingly, of the three clones that
did not exhibit increased resistance, two had multiple inserts and
one had an insert of only 62 base pairs. One clone was found that
did contain two inserts (A8-C1) and did have confirmed increased
resistance. It is not determined whether the increased resistance is
due to a combination of the two inserts or whether one of the
inserts alone is sufficient.
To verify whether the increased resistance phenotypes were a
factor of the medium used for this study, EZ RDM, or if the
medium imposed growth restrictions that influenced the increased
resistance, we did two things. We confirmed the increased
resistance of the clones T2-C1, G16-C1, and G16-C2 to
aminoglycosides in Luria-Bertani broth. We also confirmed that
a previously characterized P. aeruginosa strain, B1 [30], that has
been found to have increased resistance to aminoglycosides in
Luria-Bertani broth, maintained the elevated resistance levels in
EZ RDM.
After sequencing, we determined that there was genetic
variation within the selected populations in that not all sequenced
clones contained the same genomic region within their plasmids.
Moreover, the 40 colonies examined via sequencing, were a small
fraction of the clones surviving the selection, with approximately
1000 to a lawn of colonies remaining on the selection plates. Thus,
we expected that gene chip based studies would prove useful at
identifying the genomic regions enriched within the large number
of clones that were not among the clones isolated for sequencing.
We thus harvested the plasmids from the remaining clones and
employed the SCALEs methodology to identify the genomic-
regions contained within the plasmid-based insert DNA of selected
populations.
Microarray analysis of resistant populations
After each selection, plates containing the clones exhibiting an
increase in resistance were scraped and freezer stocks made of the
scraped cells. In order to have a sufficient amount of plasmid DNA
to detect with a microarray, cells from freezer stock were grown in
media containing carbenicillin and glucose to minimize impact of
the genomic insert (located behind a glucose-inhibited pBAD
promoter) upon growth. Thus, the microarray signal reflects not
only the clones that were present after the plate-based selection,
but also the growth rate of those clones during the recovery period.
As such, the microarray results give an indication of the ability of a
particular clone to not only survive at a specific antibiotic
concentration but also the overall fitness of that clone in the
absence of any antibiotic selective pressure.
Plasmid DNA within the clones growing upon the plates
containing 2 mg/ml tobramycin, 8 and 16 mg/ml gentamicin, as
well as 8 and 16 mg/ml amikacin, were separately prepared and
hybrized to micoarrays. The genomic regions identified from each
selection are depicted as highlighted regions along the P. aeruginosa
PAO1 genome in Figure 1. Across all selections, similar
proportions of particularly sized genomic fragments were en-
riched. Fragments of 1,500 bp or less constituted roughly two-
thirds of the enriched populations. Fragments of greater than
1,500 bp but less than 3,000 bp constituted roughly one quarter of
the enriched populations. Fragments larger than 3,000 bp made
up for approximately 10% of the enriched populations.
The genomic inserts identified via sequencing of randomly picked
clones prior to microarray experiments were among the most
prominent regions identified, with the exception of the region of the
gene encoding for topoisomerase IV subunit B, which was observed
to grow slowly in the freezer stock recovery phase (data not shown).
This genomic region is, however, enriched above background noise
and can be distinguished if signal intensities greater than 2 standard
Table 1. Sequenced clones isolated from selections along with their resistance profiles.
Clone/Strain Start Position
a Stop Position
a ORFs/genes included Product
Control: PAO2003 - - - -
Control: PAO2003+pBTB-1 - - - -
T2-C1 5,576,686 5,577,513 PA4967/parE topoisomerase IV subunit B
T2-C9 6,161,493 6,156,835 PA5472 hypothetical protein
PA5471 hypothetical protein
PA5470 probable peptide chain release factor
PA5469 conserved hypothetical protein
PA5468 probable citrate trasporter
G16-C1 5,547,691 5,551,513 PA4943 probable GTP-binding protein
PA4944/hfq host factor-I protein Hfq
PA4945/miaA d 2-isopentenylpyrophosphate transferase
PA4946/mutL DNA mismatch repair protein MutL
G16-C2 1,050,226 1,046,460 PA0963/aspS aspartyl-tRNA synthetase
PA0962 probable DNA-binding stress protein
PA0961 probable cold-shock protein
PA0960 hypothetical protein
A8-C1
b 605,929 2,567,312 PA0547 probable transcriptional regulator
PA2326 hypothetical protein
a position identified via sequencing.
b clone contains multiple inserts.
doi:10.1371/journal.pone.0006576.t001
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deviations, from the mean signal intensity are examined. A list of the
common genes and genomic regions found within the dominating
peaks of each antibiotic selection is given in Table 2, with a more
extensive table of regions identified included in supporting informa-
tion Table S1. We have examined the homology searches for the
ORFs listed as encoding hypothetical proteins, as well as examined
the COG (cluster of orthologous groups) [31] predictions and PFAM
(Protein Families Database of Alignments and hidden Markov
models) [32] predictions of these genes. Of the 17 ORFs listed in
Table 1, no predictions could be found for 7 of the ORFs. PA5211
and PA5466 had COG predictions that these genes are related to
permease activity and the COG prediction for PA2228 and PA5567
is thatofab-lactamaseclass C proteinanda GTPase, respectively. Of
other note is the PFAM prediction of PA4636 as an acetyltransferase.
Overlap among resistant populations
The enriched populations overlapped substantially across the
different aminoglycoside selections. In fact, pairwise correlation
between each of the different enriched populations was significant
(p,0.01). To assess overlap among aminoglycoside enrichments,
hierarchical clustering was performed to group selections accord-
ing to genomic enrichment profiles (Figure 2). The population of
clones surviving on 8 mg/ml gentamicin and the population of
clones surviving at 2 mg/ml tobramycin were found to be the most
similarly enriched. The gentamicin selection performed at 16 mg/
ml also grouped with these two selections while the amikacin
selections were grouped into a distinct cluster. The unselected
libraries were the least similar of all of the microarray data.
We next sought to assess enrichment patterns localized to
specific genomic regions presented in Table 1. SCALEs employs
multiple-sized libraries that can act cumulatively to give distinct
contours to plotted signal intensity across genomic position that
can be used to reveal genes or genomic regions that were enriched
during a selection (Figure 3). Figures 3A through 3D depict the
genomic regions found within clones T2-C1, T2-C9, G16-C1,
G16-C2, respectively, while 3E and 3F depict the two insert
regions found within clone A8-C1.
Discussion
The overall objective of this work was to apply the SCALEs
methodology to identify potential aminoglycoside resistance genes
present in P. aeruginosa. Reaching this objective first required that
we adapt the SCALEs methodology for use in P. aeruginosa, which
could then be followed with studies focused on revealing resistance
genes and assessing overlap in genome-scale enrichment patterns.
Adaptation of SCALEs
The adaptation of SCALEs for use in P. aeruginosa proved
challenging in several regards. First, genomic DNA extracted from
P. aeruginosa PAO1 proved to be relatively fragile and thus limited
Figure 1. Enriched genomic regions plotted along the P. aeruginosa PAO1 genome. The genomic regions highlighted were were enriched
during aminoglycoside resistance selections and identified via microarray. The aminoglycoside used in the selection and concentration are given in
the labels of the concentric rings. The unselected library sample shows that signal was present all along the genome, indicating proper genomic
coverage.
doi:10.1371/journal.pone.0006576.g001
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would have included an 8 kb library in the selections so that larger
genomic segments could be identified. Second, we chose to
perform selections on agar plates to emphasize selection for
survival instead of growth rate at increased aminoglycoside
concentrations. Due to the limited number of clones that survived
the selections, the clones harvested from the agar plates required a
step that would increase the amount of plasmid DNA that could be
extracted so that sufficient amount of genomic insert DNA would
be available to detect a signal on a microarray. We chose to grow
the cells planktonically in the presence of glucose to minimize the
impact of the insert behind the pBAD promoter of the vector. This
extra growth step needed to be taken into account while analyzing
and making predictions about the microarray data. Third, as
evidenced by the colonies that were capable of growing on higher
aminoglycoside concentrations than the bulk within the control
populations of P. aeruginosa PAO2003, mutation, recombination, or
the presence of persister cells could be a non-negligible portion of
the population. This affirmed the need to confirm that the
genomic DNA inserts within the plasmid of the selected library
clones were indeed responsible for the noted increase in resistance.
Consideration of these issues, along with host adaptability, is
essential for others seeking to extend this method to additional
bacterial species.
Interpretation of Microarray Data
Despite these difficulties, the adapted SCALEs method proved
to be successful at identifying genomic regions for which increased
copy number promotes aminoglycoside resistance. Our data
indicated that reservoirs of resistance genes overlapped signifi-
cantly across the three aminoglycosides evaluated here. This result
suggests that at least in the earliest stages in the evolution of
aminoglycoside resistance, treatment with one aminoglycoside has
the potential to result in the selection for mechanisms effective
Table 2. Common genes and genomic regions identified in
selections.
ORF/gene Product
PA0041 probable hemagglutinin
PA0727 hypothetical protein from
bacteriophage Pf1
PA0985 probable colicin-like toxin
wbpI probable UDP-N-acetylglucosamine
2-epimerase WbpI
wbpH probable glycosyltransferase WbpH
wbpG LPS biosynthesis protein WbpG
wzz O-antigen chain length regulator
- intergenic (genomic position
4,292,875-4,297,375)
PA3860 probable AMP-binding enzyme
PA3866 pyocin protein
PA5210 probable secretion pathway ATPase
PA5468 probable citrate transporter
PA5470 probable peptide chain release factor
PA2228, PA2730, PA2852, PA3860,
PA4536-PA4537, PA4636, PA5211-PA5212,
PA5412, PA5466- PA5467, PA5469,
PA5471-PA5473, PA5567
hypothetical proteins
doi:10.1371/journal.pone.0006576.t002
Figure 2. Hierarchical clustering of selection population
microarray data, displaying most enriched genetic loci. The
selection populations are represented with different columns, with
names given across the top. Enriched loci are shown in the rows.
Regions colored in yellow are less enriched. Regions colored in blue are
more enriched. Loci are listed as genomic position given in the center
base pair of the locus, ORF number, or gene name. Colored boxes on
the far right correspond to genomic regions identified in conventional
sequencing and later confirmed to increase aminoglycoside Resistance.
The following abbreviations were used to title arrays: A16 (amikacin
16 mg/ml population), A8 (amikacin 8 mg/ml population), G16 (genta-
micin 16 mg/ml population), G8 (gentamicin 8 mg/ml population), T2
(tobramycin 2 mg/ml population), and Libr (unselected mixed libraries
population).
doi:10.1371/journal.pone.0006576.g002
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sequencing, listed in Table 1. The regions highlighted are those of (A) clone T2-C1, (B) clone T2-C3, (C) clone G16-C1, (D) clone G16-C2, and the
two regions contained within clone A8-C1 (E and F). The Y-axis on each individual graph depicts the relative microarray signal intensity. The X-axis
depicts the genomic position in base pairs. Below the X-axis are the ORFs for which the depicted genomic region encompasses.
doi:10.1371/journal.pone.0006576.g003
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bolstered by our aminoglycoside resistance data (see Table 1)
where each of the five clones evaluated showed cross-resistance.
Comparison of enrichment patterns across experiments
(Figure 2) can provide some insight regarding the parallel
evolution of resistance phenotypes. For example, cross resistance
to gentamicin and tobramycin has been reported in strains
containing particular aminoglycoside modifying enzymes [6,33]
that have not shown significant resistance to amikacin. Interest-
ingly, the clustering algorithm grouped several loci with
PAO0959-0963, including potGH, moaCDE, rpmB and rpmG, among
others. Clones containing such genes were not found in our
sequencing studies, demonstrating the utility of a microarray
approach capable of identifying not only the clones present at
highest concentrations (i.e. those in Table 1) but also those clones
present at reduced concentrations that still may confer a selective
advantage and be worthy of additional study (not all clones are
present at equal concentrations in the starting population).
Given what is known about clinical resistance [25], we expected
to find a larger number of genes encoding enzymatic functions that
could potentially be acting to modify aminoglycosides or functions
involved in cell membrane permeability. Surprisingly, the majority
of the dominating regions included genes encoding transcriptional
or translational functions.
The parE gene encoding a topoisomerase IV subunit B was
identified via sequencing of a clone from the tobramycin selection
and within the microarray data from the gentamicin and
tobramycin selections. As shown in Table 1, the parE clone
exhibited 2–16 fold increased resistance across all three amino-
glycosides. Mutations within parE in P. aeruginosa [34], E. coli,
Salmonella, [35] and other species [36,37] have been shown to
increase resistance levels to quinolones antibiotics. It is known that
quinolones target two essential enzymes, DNA gyrase and
topoisomerase IV [38], involved in DNA replication, repair,
transcription, and recombination which allows for their bacteri-
cidal activity. Prior studies have linked the aminoglycoside
antibiotics with interfering with the initiation of DNA replication
[39,40], but no studies that we know of have yet been published
that show aminoglycoside antibiotics inhibiting known ParE
function, the separation of copied daughter DNA molecules,
which would explain how overexpression of parE could overcome
this effect of aminoglycosides.
Several different regions confirmed to increase resistance
contained genes encoding transcriptional and translational func-
tions [hfq (host factor I), PA0961 (probable cold-shock protein),
aspS (aspartyl-tRNA synthetase), and PA0547 (probable transcrip-
tional regulator)]. Of particular note, both hfq [41,42] and cold
shock proteins [43] are known to be involved in the stress response
and have been shown to have RNA chaperone functions allowing
them to influence the stability of mRNA transcripts. Moreover, hfq
has been implicated in small RNA regulation of mRNAs [42,44],
efficient translation of the sigma-factor encoding rpoS [45,46], and,
most recently, interference with mRNA binding to the 30S
ribosomal subunit [47], the same ribosomal subunit to which
aminoglycosides bind [23,48,49]. It is noteworthy that hfq was the
only full ORF contained within our microarray data covering this
region of the genome (Figure 3c).
These findings raised the question of whether increased copy
number of these stress-related genes lead to increased resistance
not only to aminoglycoside but to other classes of protein
inhibitors and other non-ribosomal targeting antibiotics. Increased
resistance to multiple classes of antibiotics would indicate that
increased copy number of these genes lead to a more general stress
effect on antibiotic resistance as opposed to an effect specific to
aminoglycoside resistance. No increased resistance was noted (data
not shown) for clones T2-C1, G16-C1, or G16-C2 to chloram-
phenicol ciprofloxacin, or tetracycline.
Though there were a large number of genes involved in
transcriptional and translational processes enriched within the
selected populations, as expected there was also a number of genes
encoding permeability related functions. Recently, Morita et al.
[50] have published that PA5471 is necessary for MexXY efflux
expression and thus MexXY-mediated efflux pump aminoglyco-
side resistance. Furthermore, they reported that PA5470 (anno-
tated as a probable peptide chain release factor) is not necessary
for MexXY expression. This report coincides with our microarray
data that consistently peaked over PA5471 relative to PA5470
(Figure 3b). This data in particular points out the utility of the
SCALEs approach that relies upon the use of multiple libraries
containing defined insert sizes and microarrays to efficiently
evaluate the entire library population. It should be noted that
while this genomic region was identified both by microarray and
sequencing of an individually selected clone, the directionality of
the genomic insert behind the pBAD promoter was revealed only
with sequencing. Sequencing revealed that the first ORF behind
the promoter was PA5471, leaving directionally opposite PA5468
and PA5469 dependent upon a different promoter for expression.
This highlights a limitation of identifying genomic regions with
SCALEs and bolsters the finding that PA5471 is the important
ORF related to increased resistance. The genes MexX and MexY
were not identified by this method. This is most likely due to the
size of MexX and MexY together is greater than 4 kb, the largest
size of genomic insert included in the selections.
Alterations in membrane permeability due to membrane
features may have also been responsible for the increased tolerance
of aminoglycosides to clones within the selected populations.
Selections enriched genomic segments containing genes related to
O-antigens including wbpM, wbpJ, wbpI, wbpH, wbpG (involved in
O-antigen biosynthesis), wzx, wzy, and wzz (involved in O-antigen
assembly). A definitive link between O-antigens and aminoglyco-
side resistance has yet to be established, though there have been
studies supporting the idea of altered or increased amounts of O-
antigen structures could increase resistance levels to aminoglyco-
sides. The expression of O-antigen biosynthesis and assembly
genes have been found to have a 2- to 4 log-fold decrease in
expression between amikacin-sensitive mutants generated from an
aminoglycoside-resistant clinical isolate of P. aeruginosa compared
to the resistant parent isolate [30].
Recently, Kohanski, et al. [51] published findings that
bactericidal activity of an antibiotic is due to induced hydroxyl
radical damage, caused by NADH depletion and disruption of
iron-sulfur clusters, releasing to Fe
2+ which then induces the
Fenton reaction. They reported that a decrease in NADH supply,
resulting in a decrease of superoxide generation, resulted in
increased survival to bactericidal antibiotics. Furthermore, they
reported that bactericidal drugs lead to DNA and protein damage.
This work suggested that genes that would mitigate DNA or
protein damage caused by hydroxyl radicals as well as genes
preventing the accumulation of NADH could be used to mitigate
the effects of bactericidal antibiotics. Our microarray analysis
revealed an enrichment of regions including a number of genes
involved in DNA repair and replication (including genes encoding
topoisomerase I and a DNA mismatch repair protein, mutL) as well
as a region including the gene ndh, encoding a NADH
dehydrogenase. An extended list of genes identified during each
antibiotic selection is included in the Additional file.
In conclusion, we have performed a genome-wide identification
of genomic regions in P. aeruginosa PAO1 that have the potential to
P. aeruginosa Resistance Genes
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found a large number of genomic regions could be recruited to
increase the ability of P. aeruginosa to survive under aminoglycoside
stress. A significant amount of overlap was observed among
discovered regions for which increased copy number leads to
elevated resistance levels to the three aminoglycosides examined.
We have isolated and confirmed the increase in resistance and
cross-resistance associated with five of these identified regions. The
prominent open reading frames identified are annotated to have
regulatory, transcriptional, translation, or cell envelope biogenesis
functions, or are classified as only having hypothetical functions.
The genomic regions identified provide insight into the evolution
of aminoglycoside antibiotic resistance genes and indirect insight
into the mode of action of aminoglycosides by observing how a cell
may become more tolerant of aminoglycoside-induced stress. The
number of genomic regions identified that are directly or indirectly
related to translation or post-translation processes bolster the
theory that the bactericidal action of aminoglycosides is correlated
with interference with protein synthesis. Although not the focus
here, this work opens many future research opportunities to
further study and characterize the genetic and mechanistic bases
for the increased resistance phenotypes of clones containing the
identified genomic regions. Increased study on these genomic
regions will add to the information about how a clinically relevant
species such as P. aeruginosa can employ changes within these
genomic regions to develop resistance and thus aid in planning
therapeutic strategies to circumvent the rise of resistance as well
provide information as to whether given cellular mechanisms may
be targeted for future novel antibiotic therapies. Furthermore, this
study demonstrates how the method of SCALEs can be adapted to
find genes underlying an interesting phenotype, such as resistance,
but also highlights the limitations associated with this approach
and limitations that are imposed by decisions made upon
experimental setup and experimental system in regards to the
SCALEs method.
Methods
Strains, Culturing Conditions, and Antibiotics
P. aeruginosa strains PAO1 [52] and PAO2003 (argH32 strA39 chl-2
recA2) [53] were obtained from the Pseudomonas Genetic Stock Center.
Strainswereculturedat37uC at 225 rpm in either Luria-Bertani (LB)
broth or EZ Rich Defined Medium (EZ RDM) [54] (Teknova, Inc.,
Hollister, CA) using 0.5% glycerol as a carbon source and
supplemented with 0.2% arabinose [55] where indicated. Many
standard rich mediums, such as Luria Bertani, have batch-to-batch
variations [56] and may have variations within calcium and
magnesium ion concentrations, both of which have been shown to
antagonize the affect of aminoglycosides [57]. To circumvent these
issues, we chose to use a defined medium that was still rich in amino
acids and nutrients, and thus we chose to use EZ RDM. Plate studies
were conducted on EZ RDM agar plates incubated at 37uC.
Gentamicin sulfate, tobramycin sulfate (both Research Products
International, Mount Prospect, IL) and amikacin (Fisher Scientific,
Pittsburgh, PA) were added to agar plates or medium at different
concentrations, ranging from 1 to 128 mg/ml. Carbenicillin was
added where indicated at a concentration of 100 mg/ml.
Construction of Genomic Libraries
Genomic DNA from an overnight culture of P. aeruginosa PAO1
grown in LB broth was extracted using Qiagen (Valencia, CA)
500/G Genomic-tips and Genomic DNA Buffer Set following the
protocol of the supplier with the exception of increasing the
amount of wash buffer used to 3x the recommended volume.
Partial digestion of genomic DNA was conducted with Rsa I and
Hae III (Invitrogen, Carlsbad, CA). For 1 kb and 2 kb fragments, 1
and 2 kb bands were extracted from a partial digestion of genomic
DNA resolved on a 1% standard agarose (Sigma-Aldrich, St.
Louis, MO) using a MinElute Gel Extraction Kit (Qiagen). For
4 kb-sized fragments, a partial digestion was resolved on an
analytical grade low melting point agarose gel (Promega, Madison,
WI) and 4 kb-sized fragments of DNA excised. DNA was
recovered using a GELase
TM Agarose Gel-Digesting Preparation
(EPICENTRE Biotechnologies, Madison, WI).
All plasmid extractions performed throughout this work were
prepped using either a QIAprep Spin Miniprep Kit or HiSpeed
Plasmid Midi Kit (Qiagen). Vector pBTB-1 was linearized by
digestion with Hinc II and dephosphorylated with Antarctic
Phosphatase (both New England BioLabs, Ipswich, MA). T4
DNA Ligase (Lucigen) was used to ligate linearized vector that had
not been successfully dephosphorylated. Linearized and ligated
vector were separated on a 1% agarose gel. Linearized vector was
excised from the gel and the DNA extracted using a MinElute Gel
Extraction Kit (Qiagen).
Ligation reactions and transformations were carried out using
an UltraClone
TM DNA Ligation and Transformation Kit
(Lucigen). To increase the number of transformants, prior to
transformation, ligations were precipitated with yeast tRNA [58].
Yeast tRNA precipitations were performed by adding to a 10 ml
ligation 2 mlo f1mg/ml yeast tRNA (Invitrogen), 28 ml of ultrapure
water, and 100 ml of ice-cold absolute ethanol and placing the
mixture in a 220uC freezer for 15 minutes. The mixture was then
centrifuged at 16,0006g for 15 minutes at 4uC. The pellet was
washed once with 200 ml of 70% ethanol, air dried, and finally
resuspended in 2 ml of ultrapure water. Over 100,000 transfor-
mants per library were generated with this method. Genomic
libraries were prepared from pooled colonies harvested from
transformation plates using a HiSpeed Plasmid MidiKit (Qiagen).
P. aeruginosa Transformations
Electrocompetent P. aeruginosa PAO2003 were prepared using
the method of Choi, et al. [59] in which, for each transformation,
6 mls of an overnight culture in LB medium was centrifuged at
16,0006g for 1 minute at room temperature, the pelleted cells
washed twice with room temperature 300 mM sucrose, and cells
resuspended to a total volume of 50 ml using room temperature
300 mM sucrose. These electrocompetent cells were mixed with
genomic libraries, transferred into a Fisherbrand 1 mm gap
electroporation cuvette (Fisher Scientific), and electroporated at
2.5 kV with a Eppendorf Electroporator 2510 (Eppendorf,
Westbury, NY). Transformations were recovered in 1 ml of LB
medium for 2 hours at 37uC and 225 rpm prior to plating onto
prewarmed LB agar plates supplemented with 100 mg/ml
carbenicillin. Transformants were scraped from the plates, and
resuspended in EZ RDM supplemented with glycerol. Cryogenic
freezer stocks were made with resuspended cells by combining
equal volumes of cell suspension and a 30% glycerol solution.
Sequencing and Annotation Information
Sequencing was performed by Macrogen (Seoul, Korea) using
the primers (59-CAG TCC AGT TAC GCT GGA GTC-39) and
(59-TAT CGC AAC TCT CTA CTG TTT C-39). All annotation
information was taken from the Pseudomonas Genome Database
[60].
Selections
3610
7 cells from the freezer stock of the 1 kb, 2 kb, and 4 kb
libraries were combined into to 10 ml of EZ RDM. The cells were
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were plated onto each EZ RDM agar plate containing 0.2%
arabinose and increasing concentrations of gentamicin, amikacin, or
tobramycin. P. aeruginosa PAO2003 and P. aeruginosa PAO2003
harboring pBTB-1 were used as controls. The concentration of
antibiotic that prevented growth was designated the minimum
inhibitory concentration (MIC). Plates with growth from the library
selection that had concentrations of antibiotic higher than the MICs
of the controls were saved for further studies. From these plates, a
number of colonies were individually picked, grown planktonically,
and prepared for plasmid extraction. The recovered plasmids were
then sequenced. Colonies remaining on the plates were scraped into
EZ RDM and combined with an equal volume of 30% glycerol and
saved as cryogenic freezer stock. Selection studies were performed in
duplicate to ensure repeatability (with comparable number of
surviving clones found for each selection).
Preparation of Samples for Microarray Studies
In order to obtain sufficient amounts of plasmid DNA to ensure
a detectable signal when hybridized to a microarray, 0.1 ml of
freezer stock from each selection was inoculated into 200 ml of LB
medium supplemented with carbenicillin and 0.4% glucose. These
cultures were grown to an OD600 of approximately 1. Plasmid
DNA was extracted with a HiSpeed Plasmid Midi Kit (Qiagen)
and prepared for hybridization similarly to that described
previously [1]. This entailed mixing 7.5 mg of sample plasmid
with 1,000 ng of pGIBS-DAP (ATCC#87486), 100 ng of pGIBS-
THR (ATCC#87484), 10 ng of pGIBS-TRP (ATCC#87485),
and 1 ng of pGIBS-PHE (ATCC#87483) and digesting the
mixture overnight with Rsa I and Hae III (Invitrogen). The heat-
inactivated reaction was supplemented with 10X One Phor All
buffer (Amersham Pharmacia Biotech, Piscataway, NJ) to a final
concentration of 1X and plasmid DNA was further digested and
made single stranded by the addition of 2 units of RQDNAse I
(Fisher Scientific) and 200 units of Exonuclease III (Fisher
Scientific) incubated at 37uC for 30 minutes, followed by heat
inactivation at 98uC for 20 minutes. This single-stranded DNA
was labeled with biotinylated ddUTP using and Enzo BioArray
Terminal Labeling kit (Enzo Life Sciences, Farmingdale, NY)
according to the instructions provided by the manufacturer.
Target hybridization, washing, staining, and scanning were
performed on P. aeruginosa Genome Arrays (Affymetrix, Santa
Clara, CA) at the University of Colorado DNA Microarray
Facility according to the manufacturer’s specifications.
Microarray Data Analysis
Low level probe analysis, noise reduction, and probe signal
mapping to their positions along the P. aeruginosa PAO1 genome
were performed with probe-level signals extracted from Affymetrix
.cel files as detailed in Lynch, et al. [1]. The probe signal across the
genome was broken down to segments of 125 base pairs. A
histogram of the signal intensities for every 125 bp segment
revealed the data has a large range with most segments having
relatively minimal signal and a small number of segments having
relatively large signal intensities. Removing the signal intensities
from the top 500 segments on each chip, the mean and standard
deviation of the signal intensities from the remaining segments
were calculated. To focus upon the most dominant peaks, we
removed segments that had signal intensities less than 4 standard
deviations from the mean. The 500 segments displaying the
highest signal intensities were then added back into the data.
Microbial Genome Viewer was used to depict microarray data
along genomic position [61]. Hierarchical clustering was conduct-
ed between arrays and probe signal mapped to genomic position
and corresponding ORFs using complete linkage and a Spearman
correlation. Microarray data is available through ArrayExpress
(accession: E-MEXP-2396).
Confirmation Studies
To ensure the noted changes in phenotype displayed by an
isolated colony after a selection were due to the genomic DNA
insert within pBTB-1, plasmid DNA was purified from individual
clones from each selection and transformed into freshly prepared
electrocompetent P. aeruginosa PAO2003. To confirm MICs of the
individual clones, 10 ml of freezer stock of the retransformed clones
was placed into 1 ml of EZ RDM and allowed to recover for
1 hour. 1 ml of this culture was then spotted upon EZ RDM agar
plates containing 0.2% arabinose and increasing concentrations of
amikacin, gentamicin, and tobramycin. These plates were allowed
to incubate up to 60 hours and the concentrations of antibiotic
that prevented growth noted.
Supporting Information
Table S1 Extensive table of regions identified in each selection.
Start and stop codons of regions are mentioned along with
annotation of ORFs found within those regions.
Found at: doi:10.1371/journal.pone.0006576.s001 (0.05 MB
XLS)
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